Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer
NCT00438100
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
142
Enrollment
OTHER
Sponsor class
Conditions
Breast Neoplasms
Interventions
DRUG:
Capecitabine
DRUG:
S-1
Sponsor
Japan Breast Cancer Research Network